Chiesi survey shows how Fabry drugs are failing patients fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 30, 2020 By Alex Keown
Shares of
Protalix Biotherapeutics were up nearly 7% in premarket trading after the company announced its
Phase III BRIDGE study met key objectives in treating Fabry Disease. The announcement followed previous topline data from the study released in May.
The study assessed PRX-102 (pegunigalsidase alfa), a plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A product candidate in Fabry patients who switched from treatment with agalsidase alfa. After the switch from agalsidase alfa to PRX-102, researchers noted substantial improvement in patients’ renal function as measured by mean annualized estimated Glomerular Filtration Rate. In May, the company announced positive topline results for the BRIDGE study.